Physician profile
Sami Nafoosi
NPI 1164713244
$24,049.01
in general payments reported to CMS, 2019-2025
47 companies · $1,028 in 2025
The $1,028 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,195 · 2020: $2,692 · 2021: $4,084 · 2022: $4,253 · 2023: $3,542 · 2024: $3,254 · 2025: $1,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,824.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,784.29 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,691.53 | 2019-2025 | Airsupra, Farxiga, Andexxa |
| Amgen INC. | $1,889.36 | 2019-2024 | Evenity, Repatha, Tepezza |
| Glaxosmithkline, LLC. | $1,718.97 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $1,712.72 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,620.58 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Gilead Sciences, INC. | $1,421.91 | 2019-2024 | Epclusa |
| Lilly USA, LLC | $1,111.16 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $1,038.92 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $742.22 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $723.10 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $592.66 | 2019-2024 | Camzyos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $565.47 | 2019-2024 | Xifaxan |
| Optinose US, INC. | $453.46 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $420.86 | 2019-2023 | Verquvo, Belsomra |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sami Nafoosi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.